Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: Susan G who wrote (407)	6/6/2000 10:19:00 PM
From: gao seng	Read Replies (1) \| Respond to of 746

yes the anymosity was not doing anyone any good. it is time for everyone to put their cards on the table and let their science talk for itself. I have messed up big time this week, and put my money in clpa until yesterday from thursday and then in gnsl until today from when I sold clpa yesterday. I am up from 18 to 23 and 8 to 11 but not a damn 50 to 110. what am i thinking about? I got a large position (for me anyways) in celera but I should have bought large at 50. anyways, i am not letting that prevent me from buying again tomorrow. Yes, I agree, nice is the way to play. What comes around goes around, and HGP is going down. Don't need to help it. go down, that is.

To: Susan G who wrote (407)	6/7/2000 3:23:00 AM
From: allen menglin chen	Read Replies (1) \| Respond to of 746

Probably a joint announcement! dailynews.yahoo.com Tuesday June 6 5:14 PM ET Researchers Deny Genome Map Race By PAUL RECER, AP Science Writer WASHINGTON (AP) - Leaders of two groups mapping the human genes said they are not in a race, but are trying to reach the same goal using different methods and the results will be ``complementary.'' Dr. Francis Collins, head of the National Institutes of Health program to map the human genome, and Dr. Craig Venter, president of Celera Genomics, a private Maryland company doing the same thing, shook hands and complimented each other in a brief meeting Tuesday at an NIH conference. Asked about their competition, Collins told reporters, ``racing is the wrong metaphor. I wish you would stop using it.'' Instead, Collins said the federally funded project and the private effort by Venter's company are using different ways to explore new territories. Venter agreed, saying the efforts of the two organizations are ``complementary.'' A Celera spokeswoman said results from the two efforts will be used to ``double check'' each other for accuracy in the sequencing of the 3.1 billion DNA subunits in the human genome. Venter hinted that Collins' group and his company may be in discussions about a joint announcement, but declined to be specific. He said that earlier the two groups had discussed the possibility of negotiating a cooperative agreement, but nothing was firmed up. Collins leads the National Human Genome Research Institute, which is part of an international, government-funded effort to sequence and map all of the human genes. The consortium is nearing completion of ``the working draft,'' which would mean 90 percent of the genome had been sequenced and checked for accuracy, officials said. Venter is using a computer-driven method he helped pioneer to map the genome. Celera announced last month it has sequenced the genes for one human being and may complete assembly of the sequences this month, possibly reaching the goal before NIH. A bitter rivalry has been reported between Venter and Collins' group. But the two were all smiles Tuesday. ``The controversy has been painful for both of us,'' said Venter. ``But a good effect is that the world is far more aware of genomics (study of genes) than before.'' ``Competition is a good thing,'' added Collins. ``It gets the blood stirred up.'' The two were speakers at the annual scientific conference of the General Motors Cancer Research Foundation. In his remarks, Venter said his company would ``publicly and freely'' release its map of the human genome when it was completed. The announcement came after some researchers had charged that Celera was withholding gene information to sell the data to drug companies. The government-funded effort puts its genetic data on the Internet daily, available to all. Venter said his company will do the same when the project is complete. ``A lot of credit goes to Celera,'' said Collins after the announcement. ``They are taking this data, that they paid dearly for, and making it available to the academic community.'' Asked how Celera will make a profit if the information is given away, Venter said his firm would sell its interpretation and the use of its massive gene-analysis computer system. Celera's $100 million facility in Maryland is one of the largest civilian computer assemblages in the world. Celera already has completed, or been a partner in, genetic maps for a microbe and the fruit fly, and is about a third of the way through a project to sequence genes of a strain of laboratory mice. The human genome is all of the genes that direct an individual's biological development and the functioning of the cells.